Hemophilia is a hereditary genetic disorder which impairs body's ability to control coagulation or blood clotting. In this disease, clotting factors control bleeding from a broken vessel is deficient; therefore, coagulation does not occur. Of the two types of Hemophilia, Hemophilia A has higher prevalence compared to the other variant Hemophilia B. . Acquired Hemophilia is a rare non genetic form of Hemophilia in which autoantibodies develop against the plasma coagulation factor. The development of novel coagulating factors and technological advancements are driving the growth of this market. Lack of available medicines, awareness of this disease and high cost of treatment are the major restraining factors in this market. The advancements in gene therapy and approaching approval of drugs for treatment of Hemophilia provide growth opportunities in this market.